[go: up one dir, main page]

WO1998057650A1 - Composition anti-pied d'athlete - Google Patents

Composition anti-pied d'athlete Download PDF

Info

Publication number
WO1998057650A1
WO1998057650A1 PCT/JP1998/002586 JP9802586W WO9857650A1 WO 1998057650 A1 WO1998057650 A1 WO 1998057650A1 JP 9802586 W JP9802586 W JP 9802586W WO 9857650 A1 WO9857650 A1 WO 9857650A1
Authority
WO
WIPO (PCT)
Prior art keywords
foot
athlete
composition
lactose
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1998/002586
Other languages
English (en)
Japanese (ja)
Inventor
Nobuaki Imai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to AU76745/98A priority Critical patent/AU7674598A/en
Publication of WO1998057650A1 publication Critical patent/WO1998057650A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Definitions

  • the present invention relates to an anti-athlete's foot composition.
  • an object of the present invention is to provide a new anti-athlete's foot drug, an anti-athlete's foot composition, a food form of an anti-athlete's foot food such as a drink, which is effective for the prevention and treatment of the above athlete's foot.
  • Another object of the present invention is to provide a method for preventing and treating the above athlete's foot.
  • the present inventor has conducted intensive studies for the above purpose, and as a result, has found a new fact that ingesting lactose sucrose gives a desired anti-athlete's foot effect.
  • the present invention has been completed.
  • lactose cellulose hereinafter referred to as "LS-" Is provided as an active ingredient.
  • the above composition preferably contains 0.5 to 70 g of L S in 100 g of the composition.
  • an anti-athlete's foot food for preventing and treating athlete's foot, which contains LS as an active ingredient.
  • the food is particularly preferably in the form of a beverage, the beverage comprising 100-70 g of LS 0.5-70 g and a buffer and having a pH of 4. It is preferably adjusted to 0 — 6.5.
  • L S for the manufacture of an anti-athlete's foot composition.
  • a method for preventing and treating athlete's foot that allows a human who is required to prevent or treat athlete's foot to receive an effective amount of LS.
  • a method for preventing and treating athlete's foot that allows a human who is required to prevent or treat athlete's foot to receive an effective amount of an anti-athlete's foot composition containing LS as an active ingredient.
  • the anti-athlete's foot composition of the present invention contains LS as an active ingredient.
  • the LS is a known substance represented by the following structural formula, and 0 — ⁇ — D—galactoviranoji No 1 (1 ⁇ 4) — ⁇ 1 1 D — Gnoreco Pirano Shinor 1 (1 — 2) — — D — This is displayed as Fractofuranoside.
  • Such LS is a known compound produced by various methods.
  • the LS as the active ingredient of the present invention may be one obtained by any of the above methods (a reaction mixture and a purified product thereof).
  • a reaction mixture and a purified product thereof As the method, for example, as described in Japanese Patent Publication No. 57-18905, a reno-synthase derived from a genus of Aeronocta is used.
  • Examples of the method include a method using a bacterium of the genus Oralella as described in JP-A-2-35095.
  • the above S is 100 g in the anti-athlete's foot composition of the present invention,
  • the anti-athlete's foot composition of the present invention is prepared in a pharmaceutical form or a food form.
  • the shape is not particularly limited as long as it can be taken or ingested, and may be, for example, a lump, a liquid, a syrup, a powder, or the like.
  • a pharmaceutically acceptable carrier or an edible carrier such as a commonly used excipient or diluent can be used.
  • the composition of the present invention in the above-mentioned various shapes may further contain various known additives such as a bulking agent, a sweetener, other saccharides, vitamins, flavors, coloring agents and the like. Can be done.
  • compositions of the present invention include, for example, liquid or powdered sweeteners, beverages such as soft drinks and milk drinks (drinking agents), breads, cooks, and the like.
  • beverages such as soft drinks and milk drinks (drinking agents), breads, cooks, and the like.
  • confectioneries such as candies
  • food forms such as health food forms
  • pharmaceutical forms such as powders, powders, liquids, suspensions, tablets, and foaming agents.
  • the production of the composition of the present invention in the above-mentioned various forms is carried out by adding and mixing the above-mentioned various carriers. You can do it.
  • the amount of the active ingredient in the food form is appropriately determined based on the daily intake of the food described below.
  • the beverage When formulated into a beverage form, the beverage generally contains about 0.5 to 70 g of LS as the active ingredient, preferably 100 ml, more preferably about 5 to 30 g X 1 It is prepared by dissolving in water or another dissolving agent or diluent so as to obtain a water content of 0 m 1.
  • the beverage is preferably prepared by mixing an appropriate buffering agent to have a pH of about 4.0 to 6.5, preferably about 4.5 to 6.0. Good.
  • the buffer typically, weak acids such as citric acid, tartaric acid, lactic acid, lingoic acid, and carbonic acid and salts thereof, for example, sodium citrate and sodium tartrate
  • weak acids such as citric acid, tartaric acid, lactic acid, lingoic acid, and carbonic acid and salts thereof
  • sodium citrate and sodium tartrate examples thereof include sodium, sodium phosphate, sodium lactate, sodium lactate, sodium hydrogen phosphate, sodium carbonate, and sodium hydrogen carbonate.
  • the mixing ratio of these components is appropriately determined from the range in which the obtained beverage maintains the above-mentioned appropriate pH range, and is usually up to 2% by weight, preferably about 0.05 to 0.3% by weight. obtain.
  • This buffer helps stabilize L S in the resulting beverage.
  • composition of the present invention in the form of a food such as the above-mentioned beverage, various sugars or sweeteners are added in the same manner as in a general beverage or the like.
  • carbohydrate include monosaccharides such as glucose and fructoses, disaccharides such as manoleth and sucrose, dextrin and cyclodextrin. And sugar alcohols such as xylitol, erythritol and sorbitol.
  • sweeteners include natural sweeteners (such as somatin, stevia extract, and glycerin), and synthetic sweeteners (such as saccharin and aspartame). You.
  • the proportion of such sugars or sweeteners is usually up to 15% by weight, preferably up to about 13% by weight of the foodstuffs usually obtained.
  • the composition of the present invention may contain various kinds of juices (concentrated juices) such as grapefruit, apple, orange, lemon, pineapple, banana, pear and the like. ); Vitamins (retinoyl palmitate, bisbenthiamin, riboflavin, pyridoxine hydrochloride, cyanokonokramin, sodium asconolevinate, nicotine) Water-soluble and fat-soluble vitamins, such as calcium acid amides, phenols, calcium phosphates, folic acid, piotin, coleciflucifer, oral bitumin, choline bitartrate, and tocopherol Flavoring agents; Coloring agents; Amino acids (sodium glutamate, glycine, alanine, sodium aspartate, etc.); Dietary fiber (polydextrin, black Chin, Kisanta Ngam Ara Biagamu, - Taste components (glutamic acid, inosinic acid
  • the preparation method is not particularly limited, and all the necessary components may be mixed at the same time.
  • the oil component is previously added to an appropriate oil agent.
  • an aqueous solution of the water-soluble component can be emulsified using an emulsifier.
  • the emulsification operation can be carried out according to a general method, for example, using a homomixer, a high-pressure homogenizer, or the like, according to a complete passage system or a circulation system.
  • the above components are usually mixed or emulsified at room temperature, but a slight heating operation may be employed.
  • composition of the present invention thus prepared is filled into a suitable container, and then sterilized by heat sterilization, aseptic filtration or the like according to a conventional method to obtain a product.
  • the composition of the present invention can also be prepared in the form of a suitable foam formulation that can be dissolved and dispersed in water, such as tablets, granules, powders, capsules, and the like.
  • the foam formulation is prepared using sodium hydrogen carbonate and / or sodium carbonate as a foaming component and a neutralizing agent.
  • the neutralizing agent include citric acid, tartaric acid, fumaric acid, asconolevic acid, lactic acid, and lingic acid.
  • the mixing ratio of the foaming component and the neutralizing agent is preferably selected from the range of usually 8 to 60% by weight of the foaming component and 10 to 70% by weight of the neutralizing agent.
  • Such effervescent preparations can be prepared according to the general method, for example direct powder compression or dry or wet granulation, using a further predetermined amount of calcium carbonate, if necessary. You.
  • the intake or dose of the composition of the present invention is appropriately determined depending on the purpose of use or the age, sex, weight, degree of disease, etc. of the person to whom the composition is to be applied, and is not particularly limited.
  • the composition of the present invention is a solid, generally, about 5 to 30 g of the preparation of the present invention is taken at a time, and more preferably, the solid is taken in 30 to 2 g of water. It is preferable to dissolve the drug in 100 ml and take it.
  • the present composition is in the form of a liquid such as a beverage, it is recommended to take about 30 to 200 ml per dose.
  • the preferred daily intake or dose of the composition of the present invention is The amount is preferably such that about 2 to 50 g, preferably about 3 to 20 g of the active ingredient is ingested and taken in terms of the amount of the contained active ingredient.
  • composition of the present invention can exert remarkable preventive and therapeutic effects against any of athlete's foot caused by various causative bacteria by taking or ingesting the composition.
  • each of the starting compounds was mixed and dissolved in water so as to have the composition shown in Table 1 below to prepare the composition of the present invention.
  • a fragrance and / or vitamins are appropriately blended.
  • Each formulation was made up to 100 ml with water.
  • LS55P refers to a powder containing 55% of LS.
  • the components shown in Table 5 below were mixed, water was added to make the total amount 10 Oml, and the composition of the present invention in the form of a beverage was prepared.
  • the gas volume value in the table is the same as that of the solution. Index indicating the amount of carbon dioxide contained calculated assuming that the volume of gaseous carbon dioxide dissolved is 1. Indicates that the amount of carbon oxide is large.
  • Lactic acid (mg ⁇ 8 2 20 sodium citrate (mg) 9 fl l 10 ⁇
  • Table 6 and Table 7 below summarize the patient's age, number of days of solution consumption, drinking status, pre-drinking symptoms and onset time, and the degree of improvement of athlete's foot symptoms (symptom improvement evaluation, remarks and comprehensive evaluation) by this test in Tables 6 and 7 below. .
  • the use of the anti-athlete's foot composition of the present invention can improve the symptoms of athlete's foot and suppress the deterioration of the symptoms of athlete's foot.
  • Subjective symptoms were evaluated by questionnaire survey of each patient, and evaluated on a 5-point scale according to the following criteria.
  • the subjective symptom improvement effect was determined according to the following criteria.
  • each of the above symptoms (redness, papules, blisters, pustules, maceration, erosions, and scales) were evaluated on a 5-point scale according to the following criteria, and the severity was determined by the total score.
  • the skin finding improvement rate was determined as follows, and the improvement effect was determined from the improvement rate in the same manner as described above.
  • Moderate A total score of 8 to 11 ⁇ Mild: those with a total score of 4 to 7
  • the above evaluation score of subjective symptoms and the total evaluation score of skin findings are added to obtain a difference between the sum and the sum at the start of the test (reference value).
  • the percentage was calculated as the overall improvement rate.
  • the anti-athlete's foot composition of the present invention was evaluated according to the following criteria.
  • the scale was evaluated at the scale at 2, 4, 6, and 8 weeks after the start of the test, and the maceration was evaluated at 2, 4, and 8 weeks after the start of the test, respectively. Compared with, it was recognized that there was a statistically significant difference.
  • the effectiveness of a drug is determined by the above-mentioned total number of excellent and effective cases, and the composition of the present invention has a total of 11 cases. (48%), which is considered valid.
  • 50 ml of the composition of the present invention containing 5 g of LS is administered at a rate of 50 ml per week for 3 months at a rate of 15 months. Ingested.
  • one 50 ml of the present composition in the form of an aqueous solution containing 5 g of LS is taken at an average of 1 bottle per day for 16 months. Ingested.
  • Clinical Case 6 A male patient (41 years old), who has been affected by athlete's foot for about 25 years, receives 50 ml of the composition of the present invention in the form of an aqueous solution containing 5 g of LS at a rate of 5 bottles per week for 2 years. I let it.
  • composition of the present invention when taken or ingested, can exert an excellent preventive and therapeutic effect against athlete's foot due to various causative bacteria, and is useful as an anti-athlete's foot drug.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition anti-pied d'athlète caractérisée en ce qu'elle comprend du lactosaccharose en tant que principe actif. La composition est efficace dans la prévention et le traitement du pied d'athlète.
PCT/JP1998/002586 1997-06-16 1998-06-12 Composition anti-pied d'athlete Ceased WO1998057650A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU76745/98A AU7674598A (en) 1997-06-16 1998-06-12 Antiathlete's foot composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP15878497 1997-06-16
JP9/158784 1997-06-16
JP23242797 1997-08-28
JP9/232427 1997-08-28

Publications (1)

Publication Number Publication Date
WO1998057650A1 true WO1998057650A1 (fr) 1998-12-23

Family

ID=26485791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/002586 Ceased WO1998057650A1 (fr) 1997-06-16 1998-06-12 Composition anti-pied d'athlete

Country Status (3)

Country Link
AR (1) AR016067A1 (fr)
AU (1) AU7674598A (fr)
WO (1) WO1998057650A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032530A1 (fr) * 2003-09-30 2005-04-14 Kobayashi Pharmaceutical Co., Ltd. Composition pharmaceutique pour application externe

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62238218A (ja) * 1986-04-09 1987-10-19 Idemitsu Kosan Co Ltd 抗白癬菌剤
JPS62294619A (ja) * 1986-06-16 1987-12-22 Idemitsu Kosan Co Ltd 抗白癬菌剤
JPH0733668A (ja) * 1993-07-21 1995-02-03 Maruha Corp 骨強化促進剤
WO1997000075A1 (fr) * 1995-06-14 1997-01-03 Institute Of Immunology Co., Ltd. Medicament contre le prurit cutane accompagnant l'insuffisance renale

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62238218A (ja) * 1986-04-09 1987-10-19 Idemitsu Kosan Co Ltd 抗白癬菌剤
JPS62294619A (ja) * 1986-06-16 1987-12-22 Idemitsu Kosan Co Ltd 抗白癬菌剤
JPH0733668A (ja) * 1993-07-21 1995-02-03 Maruha Corp 骨強化促進剤
WO1997000075A1 (fr) * 1995-06-14 1997-01-03 Institute Of Immunology Co., Ltd. Medicament contre le prurit cutane accompagnant l'insuffisance renale

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032530A1 (fr) * 2003-09-30 2005-04-14 Kobayashi Pharmaceutical Co., Ltd. Composition pharmaceutique pour application externe
JP2005104924A (ja) * 2003-09-30 2005-04-21 Kobayashi Pharmaceut Co Ltd 外用医薬組成物

Also Published As

Publication number Publication date
AU7674598A (en) 1999-01-04
AR016067A1 (es) 2001-06-20

Similar Documents

Publication Publication Date Title
TWI478709B (zh) A useful oral or enteral composition for the recovery of bodily functions
KR100878133B1 (ko) 탄수화물 및 전해질 보충 조성물
WO1993020718A1 (fr) Composition alimentaire inhibant la formation de produits de putrefaction intestinale
CN103384516B (zh) 含聚乙二醇的制剂
US20110142968A1 (en) Nutritional supplement
WO2007035336A2 (fr) Comprimes/granules pour boisson effervescente rehydratante
US6906038B2 (en) Methods for alleviating mucositis
CN103751327A (zh) 葡萄糖酸锌vc泡腾片
US20170080024A1 (en) Effervescent gargle tablet and method of using same
US7932288B2 (en) Composition for relieving subjective symptoms of fatigue
AU1674692A (en) Chewable antacid compositions
KR20110013685A (ko) 해양심층수, 발효흑생강 추출물 및 대추농축액을 주성분으로 하는 기능성 음료조성물
JP2002125638A (ja) 関節強化飲料
JPH0614746A (ja) 健康飲料
EP3290041B1 (fr) Composition de soin buccal
TW200800153A (en) Composition for inhibiting low blood sugar syndrome
WO1998057650A1 (fr) Composition anti-pied d'athlete
JPH0638707A (ja) 腸内腐敗産物生成抑制食品組成物
RU2578391C2 (ru) Напиток
JPH0549444A (ja) 耐久力増強用食品
JP2021100421A (ja) 肝機能改善用組成物及び肝機能改善用食品組成物
JPWO1998057650A1 (ja) 抗水虫組成物
JP4435882B2 (ja) アルコール吸収抑制組成物
CN111511222A (zh) 用于钙补充的组合物
JPH11124390A (ja) 皮膚疾患治療組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN ID JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 2000573167

Format of ref document f/p: F